Journal article
PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study
Oral oncology, Vol.149, 106634
02/2024
DOI: 10.1016/j.oraloncology.2023.106634
PMID: 38118249
Abstract
Currently, no systemic treatments are approved for patients with recurrent and/or metastatic (R/M) adenoid cystic carcinoma (ACC). PRT543, a protein arginine methyltransferase 5 inhibitor that downregulates NOTCH1 and MYB signalling in tumours, is a potential candidate for R/M ACC treatment. We report the safety, tolerability and preliminary efficacy of PRT543 in a dose-expansion cohort of patients with R/M ACC.
This phase I multicentre, open-label, sequential-cohort, dose-escalation and dose-expansion study (NCT03886831) enrolled patients with advanced solid tumours and select haematologic malignancies. Dose-escalation study design and results were reported previously. In the dose expansion, patients with R/M ACC received recommended phase II doses of 35 or 45 mg PRT543 orally on days 1-5 of each week. Primary objectives were to establish the safety and tolerability of PRT543. Secondary objectives included efficacy.
Between February 2019 and May 2022, 56 patients with ACC were enrolled across 23 US sites and received either 35 mg (n = 28) or 45 mg (n = 28) of PRT543. Overall, 23% of patients experienced a grade 3 treatment-related adverse event, most commonly anaemia (16%) and thrombocytopaenia (9%). No grade 4/5 treatment-emergent adverse events were reported. Median progression-free survival was 5.9 months (95% CI: 3.8-8.3). The clinical benefit rate was 57% (95% CI: 43-70). Overall response rate (per Response Evaluation Criteria in Solid Tumours v1.1) was 2%, with 70% of patients having stable disease.
In this analysis, PRT543 was tolerable, and the observed efficacy was limited in patients with R/M ACC.
Details
- Title: Subtitle
- PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study
- Creators
- Renata Ferrarotto - The University of Texas MD Anderson Cancer CenterPaul L Swiecicki - University of MichiganDan P Zandberg - University of Pittsburgh School of MedicineRobert A Baiocchi - The Ohio State UniversityRobert Wesolowski - The Ohio State UniversityCristina P Rodriguez - University of WashingtonMeredith McKean - Sarah Cannon Research InstituteHyunseok Kang - University of California, San FranciscoVarun Monga - University of IowaRajneesh Nath - Banner MD Anderson Cancer Center, Gilbert, AZ, USANeil Palmisiano - Thomas Jefferson UniversityNaveen Babbar - Prelude Therapeutics, Research and Development, Wilmington, DE, USAWilliam Sun - Prelude Therapeutics, Research and Development, Wilmington, DE, USAGlenn J Hanna - Center for Head and Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, MA, USA
- Resource Type
- Journal article
- Publication Details
- Oral oncology, Vol.149, 106634
- DOI
- 10.1016/j.oraloncology.2023.106634
- PMID
- 38118249
- NLM abbreviation
- Oral Oncol
- eISSN
- 1879-0593
- Language
- English
- Electronic publication date
- 12/19/2023
- Date published
- 02/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984533448802771
Metrics
5 Record Views